Bio-Rad QX200 Droplet Digital PCR (ddPCR) System

This notice of intent announces NIH’s plan to award a firm‑fixed‑price purchase order on a sole‑source basis to Bio‑rad Laboratories for the QX200 Droplet Digital PCR (ddPCR) System, a proprietary laboratory instrument used for absolute nucleic‑acid quantification. The agency is seeking capability statements from any responsible source that can demonstrate an equivalent product, though the system is claimed to be uniquely supplied by Bio‑rad. Submissions are due by 9:00 a.m. EDT on September 17 2026, with award expected about five days later. The procurement is governed by FAR 6.302‑1 (only one responsible source). • Sole‑source acquisition of a high‑precision digital PCR instrument. • Intended for NIH research laboratories (likely biomedical/clinical research). • Capability statements accepted from any vendor able to meet technical specs, but award will go to Bio‑rad unless an equivalent is proven. • Deadline: September 17 2026; award anticipated around September 22 2026. • No explicit contract value disclosed; typical QX200 system price range $100k‑$200k.